#3 - Caribou Biosciences (NASDAQ:CRBU)
Caribou Biosciences Inc. (NASDAQ: CRBU) is working on what it describes as the next generation of CRISPR genome-editing technology. The company has created its proprietary chRDNA genome-editing technology that according to Caribou improves upon CRISPR technology by making more precise genome edits.
CRBU stock is down 70% in 2024, which is typical of a stock with just a $171 million market cap. However, the stock has rallied somewhat after an earnings report in which it beat revenue and earnings expectations. The company also has a cash foundation over $370 million which is expected to keep it funded through the first quarter of 2026.
Since the report, the Royal Bank of Canada (NYSE: RY) reiterated its Outperform rating on CRBU stock with a $14 price target. That tracks with overall analyst sentiment which has a Moderate Buy rating on the stock with a $15 price target.
About Caribou Biosciences
Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.
Read More - Current Price
- $2.19
- Consensus Rating
- Buy
- Ratings Breakdown
- 4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $10.20 (365.8% Upside)
